Pituitary function and IGF-I levels following ischemic stroke

Cerebrovascular Diseases

Volumn 31, Issue 2, 2011, Pages 163-169

  Boehncke, Sandra ^a   Ackermann, Hanns ^a   Badenhoop, Klaus ^a   Sitzer, Matthias ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

IGF I; Ischemic stroke; NIHSS; Pituitary dysfunction; Stroke outcome

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR; SOMATOMEDIN C;

ADRENAL INSUFFICIENCY; ADULT; AGED; ANXIETY DISORDER; ARTICLE; BRAIN ISCHEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; FEMALE; HORMONE RESPONSE; HUMAN; HYPOPHYSIS DISEASE; HYPOPHYSIS FUNCTION; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; ANXIETY; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; DEPRESSION; DISABILITY EVALUATION; FEMALE; GERMANY; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PITUITARY FUNCTION TESTS; PITUITARY GLAND; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STROKE; TIME FACTORS;

EID: 78649694404     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321738     Document Type: Article

References (24)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747-1757.
2. Ferro JM, Caeiro L, Santos C: Poststroke emotional and behavior impairment: a narrative review. Cerebrovasc Dis 2009; 27(suppl 1):197-203.
3. Wallymahmed ME, Foy P, Mac Farlane IA: The quality of life of adults with growth hormone deficiency: a comparison with diabetic patients and control subjects. Clin Endocrinol 1999; 51: 333-338.
4. Schneider HJ, Kreitschmann-Andermahr I, Ghigo E, Stalla GK, Agha A: Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review. JAMA 2007; 298: 1429-1438.
5. Van Rijn MJ, Slooter AJ, Bos MJ, Catarino CF, Koudstaal PJ, Hofman A, Breteler MM, van Duijn CM: Insulin-like growth factor I promoter polymorphism, risk of stroke, and survival after stroke: the Rotterdam Study. J Neurol Neurosurg Psychiatry 2006; 77: 24-27.
6. Bondanelli M, Ambrosio MR, Onofri A, Bergonzoni A, Lavezzi S, Zatelli MC, Valle D, Basaglia N, degli Uberti EC: Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome. J Clin Endocrinol Metab 2006; 91: 3928-3934.
7. European Stroke Initiative Executive Committee and the EUSI Writing Committee: European Stroke Initiative Recommendations for Stroke Management - Update 2003. Cerebrovasc Dis 2003; 16: 311-337.
8. Lyden P, Lu M, Jackson C, Marler J, Kothari R, Brott T, Zivin J, NINDS tPA Stroke Trial Investigators: Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. Stroke 1999; 30: 2347-2354.
9. Banks JL, Marotta CA: Outcomes validity and reliability of the Modified Rankin Scale: implications for stroke clinical trials - A literature review and synthesis. Stroke 2007; 38: 1091-1096.
10. Mahoney FI, Barthel D: Functional evaluation: the Barthel Index. Maryland State Med J 1965; 14: 56-61.
11. Zigmond A, Snaith R: The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67: 361-370.
12. Allolio B, Schulte HM: Praktische Endokrinologie. München, Urban & Schwarzenberg, 1996, pp 219-227.
13. Johansson P, Olsson T, Carlberg B, Karlsson K, Fagerlund M: Hypercortisolism after stroke - partly cytokine-mediated? J Neurol Sci 1997; 147: 43-47.
14. Astrom M, Olsson T, Asplund K: Different linkage of depression to hypercortisolism early versus late after stroke: a 3-year longitudinal study. Stroke 1993; 24: 52-57.
15. Weber-Hamann B, Blum WF, Kratzsch J, Gilles M, Heuser I, Deuschle M: Insulin-like growth factor-I (IGF-I) serum concentrations in depressed patients: relationship to saliva cortisol and changes during antidepressant treatment. Pharmacopsychiatry 2009; 42: 23-28.
16. Deuschle M, Blum WF, Strasburger CJ, Schweiger U, Weber B, Korner A, Standhardt H, Gotthardt U, Schmider J, Pflaum CD, Heuser I: Insulin-like growth factor-I (IGFI) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology 1997; 22: 493-503.
17. Arwert LI, Deijen JB, Müller M, Drent ML: Long-term growth hormone treatment preserves GH-induced memory and mood improvements: a 10-year follow-up study in GH-deficient adult men. Horm Behav 2005; 47: 343-349.
18. Tanriverdi F, Dagli AT, Karaca Z, Unluhizarci K, Selcuklu A, Casanueva FF, Kelestimur F: High risk of pituitary dysfunction due to aneurysmal subarachnoid haemorrhage: a prospective investigation of anterior pituitary function in the acute phase and 12 months after the event. Clin Endocrinol 2007; 67: 931-937.
19. Kooijman R, Sarre S, Michotte Y, De Keyser J: Insulin-like growth factor I: a potential neuroprotective compound for the treatment of acute ischemic stroke? Stroke 2009; 40:e83-e88.
20. Denti L, Annoni V, Cattadori E, Salvagnini MA, Visioli S, Merli MF, Corradi F, Ceresini G, Valenti G, Hoffman AR, Ceda GP: Insulin- like growth factor 1 as a predictor of ischemic stroke outcome in the elderly. Am J Med 2004; 117: 312-317.
21. Schneider HJ, Aimaretti G, Kreitschmann- Andermahr I, Stalla GK, Ghigo E: Hypopituitarism. Lancet 2007; 369: 1461-1470.
22. Reschke K, Pfeiffer AF, Lehnert H: Hormone replacement therapy. What is reliable? Internist 2003; 44: 98-109.
23. Adams HP, Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR, Woolson RF, Hansen MD: Baseline NIH Stroke Scale score strongly predicts outcome after stroke: a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999; 53: 126-131.
24. Appelros P, Terént A: Characteristics of the National Institute of Health Stroke Scale: results from a population-based stroke cohort at baseline and after one year. Cerebrovasc Dis 2004; 17: 21-27.